
Fractyl Health, Inc. Common Stock (GUTS)
Fractyl Health, Inc. is a clinical-stage biotech company focused on developing transformative treatments for metabolic and gastrointestinal diseases. Known for its innovative approach to advancing therapies targeting conditions like type 2 diabetes and other metabolic disorders, the company emphasizes minimally invasive procedures and novel technologies to improve patient outcomes.
Company News
Fractyl Health appointed Christopher Thompson, M.D. and Ian Sheffield to its Board of Directors to strengthen clinical execution and strategic growth in metabolic therapeutics, focusing on obesity and type 2 diabetes treatments.
Shares of Cal-Maine Foods, Inc. (NASDAQ: CALM) rose sharply in today’s pre-market trading after the company reported upbeat results for its fourth quarter. The company reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.46 per share, according to data from Benzinga Pro. Cal-Maine Foods shares jumped 8.3% to $63.80 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers LAMF Global Ventures Corp. I (NASDAQ: LGVC) rose 148.9% to $26.79 in pre-market trading. ViewLAMF Global Ventures Corp. I shareholders approved previously announced business combination with Nuvo Group Ltd. Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH) gained 68.3% to $0.5389 in pre-market trading after gaining 13% on Tuesday. OneMedNet Corporation (NASDAQ: ONMD) gained 34.1% to $1.06 in pre-market trading. OneMedNet announced it entered a securities purchase agreement dated Mar. 28 providing up to $4.54 million in funding through private placement of senior convertible notes. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares gained 28.1% to $5.01 in pre-market trading. Vanda Pharmaceuticals' Fanapt® received U.S. FDA approval for the acute treatment of Bipolar I Disorder. Inspire Veterinary Partners, Inc. (NASDAQ: IVP) gained 16% to $0.0545 ...
BBB Foods’ stock rises in its first day of trading as IPO market churns out deals.